These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1162 related articles for article (PubMed ID: 33980657)

  • 1. COVID-19 controlled human infection studies: worries about local community impact and demands for local engagement.
    Lee K; Eyal N
    J Med Ethics; 2021 Aug; 47(8):539-542. PubMed ID: 33980657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.
    Amit S; Regev-Yochay G; Afek A; Kreiss Y; Leshem E
    Lancet; 2021 Mar; 397(10277):875-877. PubMed ID: 33610193
    [No Abstract]   [Full Text] [Related]  

  • 4. Surveillance Metrics of SARS-CoV-2 Transmission in Central Asia: Longitudinal Trend Analysis.
    Post LA; Benishay ET; Moss CB; Murphy RL; Achenbach CJ; Ison MG; Resnick D; Singh LN; White J; Chaudhury AS; Boctor MJ; Welch SB; Oehmke JF
    J Med Internet Res; 2021 Feb; 23(2):e25799. PubMed ID: 33475513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral and social science in support of SARS-CoV-2 vaccination: National Institutes of Health initiatives.
    Hunter CM; Chou WS; Webb Hooper M
    Transl Behav Med; 2021 Jul; 11(7):1354-1358. PubMed ID: 34080616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [SARS-CoV-2 vaccines].
    Benfield TL; Helweg-Larsen J
    Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of Rheumatologists.
    Santosa A; Xu C; Arkachaisri T; Kong KO; Lateef A; Lee TH; Leong KH; Low AHL; Sriranganathan MK; Tan TC; Teng GG; Thong BY; Fong W; Lahiri M
    Int J Rheum Dis; 2021 Jun; 24(6):746-757. PubMed ID: 33973379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What Now? Health Challenges for 2021.
    Flaskerud JH
    Issues Ment Health Nurs; 2021 Mar; 42(3):299-303. PubMed ID: 33493083
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of vaccines for SARS-CoV-2.
    Ng WH; Liu X; Mahalingam S
    F1000Res; 2020; 9():. PubMed ID: 32850116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 vaccine trials: The use of active controls and non-inferiority studies.
    Fleming TR; Krause PR; Nason M; Longini IM; Henao-Restrepo AM
    Clin Trials; 2021 Jun; 18(3):335-342. PubMed ID: 33535811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Problematic Covid-19 vaccine trials in times of vaccine nationalism.
    Ravinetto R
    Indian J Med Ethics; 2021; VI(2):1-7. PubMed ID: 33908359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frontrunners in the race to develop a SARS-CoV-2 vaccine.
    Russell RL; Pelka P; Mark BL
    Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of SARS-CoV-2 positive cases beyond health-care professionals or social and health-care facilities.
    Deiana G; Azara A; Dettori M; Delogu F; Vargiu G; Gessa I; Arghittu A; Tidore M; Steri G; Castiglia P
    BMC Public Health; 2021 Jan; 21(1):83. PubMed ID: 33413218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccines for COVID-19: An Overview.
    Lang TF; Eber RM; Reddy MS
    Compend Contin Educ Dent; 2021 Jun; 42(6):298-304; quiz 305. PubMed ID: 34077664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19: opportunities for public health ethics?
    Maeckelberghe E
    J R Coll Physicians Edinb; 2021 Jun; 51(S1):S47-S52. PubMed ID: 34185038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. India's crusade against COVID-19.
    Madkaikar M; Gupta N; Yadav RM; Bargir UA
    Nat Immunol; 2021 Mar; 22(3):258-259. PubMed ID: 33627877
    [No Abstract]   [Full Text] [Related]  

  • 20. Community knowledge, attitude and practices to SARS-CoV-2 disease 2019 (COVID-19): A cross-sectional study in Woldia town, Northeast Ethiopia.
    Molla KA; Abegaz SB
    PLoS One; 2021; 16(4):e0250465. PubMed ID: 33878139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.